ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

  • Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting

    ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial

    Mark C. Genovese1, Michael Weinblatt2, Jacob A Aelion3, Heikki T. Mansikka4, Paul M. Peloso4, Kun Chen4, Yihan Li4, Ahmed A. Othman4, Amit Khatri4, Nasser S. Khan4 and Robert J. Padley4, 1Stanford University Medical Center, Palo Alto, CA, 2Brigham and Women’s Hospital, Boston, MA, 3West Tennessee Research Institute, Jackson, TN, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
  • Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting

    The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy

    Daniel Erhardt1, Brian C Sauer2, Chia-Chen Teng2, Ted R. Mikuls3, Jeffrey R. Curtis4 and Grant W. Cannon2, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 3Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…
  • Abstract Number: 921 • 2016 ACR/ARHP Annual Meeting

    The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ

    Robert Hennze1, Thomas Schlitt1, Thomas Peters1, Irina Koroleva2, Rebecca Torene2, Xiaoyu Jiang3, Marija Curcic Djuric1, Anis Mir1, Frank Kolbinger1 and Christine Huppertz1, 1Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland, 2Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, 3Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambdrige, MA

    Background/Purpose:   In order to better understand the IL-17A signaling pathway we have analyzed the effects of IL-17A in human primary synovial fibroblasts (SF), a…
  • Abstract Number: 1568 • 2016 ACR/ARHP Annual Meeting

    Microrna-17 Suppresses TNF-α Signaling By Reducing TRAF2 and cIAP2 Association in Rheumatoid Arthritis Synovial Fibroblasts

    Nahid Akhtar1, Anil Singh2 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Washington State University, College of Pharmacy, Spokane, WA

    Background/Purpose:   TNF-α is a major cytokine implicated in rheumatoid arthritis (RA) and its expression has shown to be regulated at transcriptional and posttranscriptional levels.…
  • Abstract Number: 2155 • 2016 ACR/ARHP Annual Meeting

    Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts

    Alvaro Valin1, Yolanda Ruano2, Manuel J. Del Rey3, Carmen M. García-Herrero3, Eduardo Martín-Guerrero1, Beatriz Bravo4, Juan D. Cañete5, José L. Rodríguez-Peralto2 and Jose L. Pablos3,6, 1Grupo de Enfermedades Inflamatorias y Autoimmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 2Pathology Department, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 3Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 4Servicio de Traumatología y Cirugía Ortopédica, Hospital 12 de Octubre, Madrid, Spain, 5Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, 6Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain

    Background/Purpose:  Although elevated IL-6 and its soluble receptor (sIL6R) have been found in the serum and synovium of arthritic patients, the molecular mechanisms by which…
  • Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting

    Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

    M. Victoria Hernández1, Carlos Sánchez-Piedra2, Jose Inciarte-Mundo1, Fernando Sanchez-Alonso2, Javier Manero3, Rosa Roselló4, Eva Pérez-Pampin5, Carlos Rodriguez-Lozano6, Cesar Diaz-Torné7, Raimon Sanmarti1, Juan J. Gómez-Reino5 and Biobadaser 2.0 Study Group, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 4Rheumatology, H San Jorge, Huesca, Spain, 5Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, 6Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 7Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose:  Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…
  • Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting

    Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate:  a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab

    Arthur Kavanaugh1, Ronald F. van Vollenhoven2, Benjamin A. Wolfe3, Stefan Florentinus3, Su Chen3, Jessica L. Suboticki3 and Josef S. Smolen4, 1Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA, 2Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 3AbbVie Inc., North Chicago, IL, 4Medical University of Vienna, Vienna, Austria

    Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…
  • Abstract Number: 3012 • 2016 ACR/ARHP Annual Meeting

    Clinical Predictors of TNF-Inhibitor Free Disease Control in Patients with Rheumatoid Arthritis after Stopping TNFi Treatment: Results from a Dutch Multicentre Pragmatic Open-Label Randomized Controlled Trial.

    Marjan Ghiti Moghadam1, Harald E. Vonkeman2, Peter M. ten Klooster3,4, Femke Lamers-Karnebeek5, Janneke Tekstra6, Barbara van Schaeybroeck7, Ruth Klaasen8, Marieke van Onna9, Hein J. Bernelot Moens10, H. Visser11, Annemarie Schilder12, Mark R. Kok13, Robert Landewé14, Piet L.C.M. van Riel15, Mart A.F.J. van de Laar16 and Tim Jansen17, 1rheumatology, Arthritis Centre Twente, University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands, Enschede, Netherlands, 2Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 3Psychology, Health & Technology, University of Twente, Enschede, Netherlands, 4Arthritis Centre Twente, University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands, Enschede, Netherlands, 5rheumatology, RadboudUMC, Nijmegen, Netherlands, 6Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 7Rheumatology, Albert Schweitzer MC, Dordrecht, Netherlands, 8Rheumatology, Meander MC, Amersfoort, Netherlands, 9Huispostnummer F4-105, PO Box, AMC medical centre, Amsterdam, Netherlands, 10rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, 11Department of Rheumatolgy, Rijnstate Hospital Arnhem, Arnhem, Netherlands, 12Rheumatology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, 13Rheumatology, Maaststadziekenhuis, Rotterdam, Netherlands, 14University of Amsterdam, Amsterdam, Netherlands, 15IQ Health Care, radboudUMC, Nijmegen, Netherlands, 16Rheymatology, Arthritis Centre Twente, University of Twente and Medisch Spectrum Twente, Enschede, Netherlands, 17VieCuri Medical Center, Venlo, Netherlands

    Background/Purpose:   Tumor Necrosis Factor inhibitor (TNFi) free prolonged acceptable disease control in patients with rheumatoid arthritis (RA), in stable remission or low disease activity…
  • Abstract Number: 3220 • 2016 ACR/ARHP Annual Meeting

    Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentiate Between TNF-Alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis

    Theresa L. Wampler Muskardin1, Wei Fan2, Zhongbo Jin3, Mark A. Jensen4, Jessica M. Dorschner3, Yogita Ghodke-Puranik3, Kerry Wright1, John M. Davis III5, Eric L. Matteson1, Clement Michet Jr.1, Thomas G. Mason II6, Scott T. Persellin7, Daniel Schaffer1, Betty Dicke1, Danielle Vsetecka3 and Timothy B. Niewold8, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 4Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN, 6Division of Rheumatology - Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 7Department of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 8Rheumatology and Immunology, Mayo Clinic, Rochester, MN

    Background/Purpose: In rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy, and remission is…
  • Abstract Number: 3225 • 2016 ACR/ARHP Annual Meeting

    Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with Rheumatoid Arthritis

    Mark C. Genovese1, Michael Weinblatt2, Heikki T. Mansikka3, Paul M. Peloso3, Kun Chen3, Yihan Li3, John Liu3 and Robert J. Padley3, 1Stanford University Medical Center, Palo Alto, CA, 2Brigham and Women’s Hospital, Boston, MA, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: ABT-122 is a dual variable domain immunoglobulin (DVD-Ig™) that targets human tumor necrosis factor-α (TNF-α) and interleukin-17A (IL-17A). The object was to investigate the…
  • Abstract Number: 495 • 2016 ACR/ARHP Annual Meeting

    The Relative Performance of 28-Joint Disease Activity Score Based on C-Reactive Protein with Three Versus Four Components in Patients with Rheumatoid Arthritis

    Ferdinand Breedveld1, Xin Wang2, Anabela Cardoso3 and Edward Keystone4, 1Leiden Univ Medical Center, Leiden, Netherlands, 2AbbVie Inc., North Chicago, IL, 3Torre Oriente, AbbVie, Lisboa, Portugal, 4Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada

    Background/Purpose: The commonly used version of the 28-joint disease activity score based on C-reactive protein (DAS28-CRP4) includes swollen and tender joint counts (S/TJC), CRP and…
  • Abstract Number: 598 • 2016 ACR/ARHP Annual Meeting

    An Assessment of the Correlation Between Gender and Anticipated Drug Retention to TNF Inhibitors: A Meta-Regression Analysis

    Cathy Lee Ching1, Elie Donath2 and Suresh Kumar3, 1Internal Medicine, University of Miami Miller School of Medicine/ JFK Med Ctr, Palm Beach Regional Campus GME Consortium, Atlantis, FL, 2Internal Medicine, University of Miami Miller School of Medicine, JFK Med Ctr, Palm Beach Regional Campus GME Consortium, Atlantis, FL, 3Rheumatology, Veterans Affairs Medical Center of West Palm Beach, West Palm Beach, FL

    Background/Purpose:  It is generally believed that a wide variety of patient-specific factors, and in particular gender, are likely to influence the response and tolerability of…
  • Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting

    Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study

    Rishi J. Desai1, Daniel H. Solomon2, Sebastian Schneeweiss3, Goodarz Danaei4, Katherine Liao5 and Seoyoung C. Kim6, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Boston, MA, 3Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Harvard School of Public Health, Boston, MA, 5Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 6Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…
  • Abstract Number: 1096 • 2015 ACR/ARHP Annual Meeting

    B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis

    Victor Wang1, Nida Meednu1, Wen Sun2, Javier Rangel-Moreno3, Lianping Xing2 and Jennifer H. Anolik1, 1Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY, 3Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease, which causes joint inflammation and bone loss. Inflammation-mediated joint damage is linked to the imbalance of…
  • Abstract Number: 1364 • 2015 ACR/ARHP Annual Meeting

    Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation

    Giulio Cavalli1, Marije Koenders2, Lorenzo Dagna3, Alberto Mantovani4, Cecilia Garlanda4, Leo Joosten5 and Charles Dinarello1, 1Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy, 4Research Institute Humanitas, Milan, Italy, 5Internal Medicine, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: Characterized as a fundamental inhibitor of innate inflammation, IL‑1 family member IL‑37 is expressed in the synovia of patients with rheumatoid arthritis. We investigated…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology